PCP
DGX icon

Perbak Capital Partners’s Quest Diagnostics DGX Stock Holding History

Perbak Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,224
Closed -$220K – 318
2025
Q2 		$220K Buy
+1,224
New +$213K 0.05% 265

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Perbak Capital Partners's DGX Position: Q3 2025 in Review

Perbak Capital Partners sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 1,224 shares — an estimated $220K sold.

Perbak Capital Partners first reported a position in DGX in Q2 2025 and held it in 1 quarter. The position peaked at $220K in Q2 2025. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Perbak Capital Partners reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Perbak Capital Partners sold 1,224 Quest Diagnostics shares in Q3 2025, an estimated $220K.
  • Perbak Capital Partners first reported a position in Quest Diagnostics in Q2 2025 and held it in 1 quarter.
  • Perbak Capital Partners's Quest Diagnostics position peaked at $220K in Q2 2025.
  • 1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Perbak Capital Partners's 13F filing for Q3 2025, filed 13 Nov 2025.